Lotus Pharmaceutical Co., Ltd.

Informe acción TWSE:1795

Capitalización de mercado: NT$85.4b

Salud financiera de hoja de balance de Lotus Pharmaceutical

Salud financiera controles de criterios 3/6

Lotus Pharmaceutical tiene un patrimonio de accionistas total de NT$17.3B y una deuda total de NT$11.3B, lo que sitúa su ratio deuda-patrimonio en 65.4%. Sus activos y pasivos totales son NT$33.0B y NT$15.7B respectivamente. El BAIT de Lotus Pharmaceutical es de NT$5.1B, por lo que su ratio de cobertura de intereses es de 10.1. Tiene efectivo e inversiones a corto plazo que ascienden a NT$1.8B.

Información clave

65.4%

Ratio deuda-patrimonio

NT$11.33b

Deuda

Ratio de cobertura de intereses10.1x
EfectivoNT$1.77b
PatrimonioNT$17.33b
Total pasivoNT$15.66b
Activos totalesNT$32.99b

Actualizaciones recientes sobre salud financiera

Recent updates

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$12.7B) de 1795 superan a sus pasivos a corto plazo (NT$4.5B).

Pasivo a largo plazo: Los activos a corto plazo de 1795 (NT$12.7B) superan a sus pasivos a largo plazo (NT$11.1B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 1795 (55.2%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 1795 ha crecido de 62.1% a 65.4% en los últimos 5 años.

Cobertura de la deuda: La deuda de 1795 no está bien cubierta por el flujo de caja operativo (14.2%).

Cobertura de intereses: Los pagos de intereses de la deuda de 1795 están bien cubiertos por el BAIT (10.1x cobertura).


Hoja de balance


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target